We sat down with Dr. Eid at his New York City office to ask him about the latest developments in penile implant therapy.
CORAL study chair Lance Dworkin, MD, discusses the controversial finding with Renal & Urology News.
Rising readmission rates of subsequent sepsis have given urologic surgeon Jeremy Grummet, MBBS, MS, FRACS, pause.
Immunologic mismatch may no longer be a barrier between living kidney donors and recipients.
Some may find it surprising that Dr. Critz generally considers RP to be the go-to treatment for localized disease.
A digital sensing platform could allow patients with chronic kidney ailments or diabetes to test their own urine albumin levels.
Urologist Ronald K. Loo, MD, of Southern California Permanente Medical Group and colleagues created and validated a Hematuria Risk Index.
Hyponatremia authority Dr. Juan Carlos Ayus receives calls all the time from fellow nephrologists who have questions.
Radium-223 was approved in May 2013 for the treatment of mCRPC with symptomatic bone metastases and no visceral disease.
A nascent technology combines laser optics and ultrasound to distinguish between benign and malignant prostate tissue.
Dr. Crispen highlights the advantages and challenges of active surveillance for small renal masses.
David O. Sussman, DO, has been ready to educate urology colleagues on the appropriate use of Botox.
The MENTOR study is poised to change first-line-treatment recommendations for idiopathic membranous nephropathy.
Provenge is a breatkthrough treatment option for men with asymptomatic or minimally symptomatic metastatic, hormone-resistant PCa.
The scar tissue that forms on sections of some glomeruli in FSGS will lead to kidney failure if left untreated.